Low density lipoprotein apolipoprotein B metabolism: Comparison of two methods to establish kinetic parameters

Atherosclerosis

Volumn 144, Issue 1, 1999, Pages 159-166

  Parhofer, Klaus G ^a,b   Hugh, P ^a   Barrett, R ^a   Schwandt, Peter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b University of Washington   (United States)

Author keywords

Apheresis; Non steady state kinetics; Stable isotopes; Tracer

Indexed keywords

APOLIPOPROTEIN B; DEUTERIUM; LEUCINE; LOW DENSITY LIPOPROTEIN; TRACER;

APHERESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; KINETICS; LIPID METABOLISM; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; LINEAR MODELS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0345712317     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00050-7     Document Type: Article

References (28)

1. Fisher WR, Zech LA, Kilgore LL, Stacpoole PW. Metabolic pathways of apolipoprotein-B in heterozygous familial hypercholesterolemia - studies with a H-3 leucine tracer. J Lipid Res 1991;32:1823-36.
2. Vega GL, Denke MA, Grundy SM. Metabolic basis of primary hypercholesterolemia. Circulation 1991;84:118-28.
3. Kesaniemi YA, Vega GL, Grundy SM. Kinetics of apolipoprotein B in normal and hyperlipidemic man: review of current data. In: Berman M, Grundy SM, Howard BV, editors. Lipoprotein Kinetics and Modeling. New York: Academic Press, 1982:181-205.
4. Beltz WF, Kesaeniemi YA, Howard BV, Grundy SM. Development of an integrated model for analysis of the kinetics of apolipoprotein B in plasma very low density lipoproteins, itermediate density lipoproteins, and low density lipoproteins. J Clin Invest 1985:76:575-85.
5. Parhofer KG, Barren PHR, Bier DM, Schonfeld G. Determination of kinetic parameters of apolipoprotein-B metabolism using amino acids labeled with stable isotopes. J Lipid Res 1991:32:1311-23.
6. Ramakrishnan R, Arad Y, Wong S, Ginsberg HN. Nonuniform radiolabeling of Vldl apolipoprotein-B - implications for the analysis of studies of the kinetics of the metabolism of lipoproteins containing apolipoproteinB. J Lipid Res 1990;31:1031-42.
7. Barrett PHR. Stable isotopes and lipoprotein kinetics: endogenous labeling and complex systems. Baill Clin Endocrin Metab 1996;3:71-2.
8. Foster DM, Barrett PHR, Toffolo G, Beltz WF, Cobelli C. Estimating the fractional catabolic rate of plasma apolipoproteins and lipids from stable isotope data. J Lipid Res 1993;34:2193-205.
9. Eriksson M, Berglund L, Gabrielsson J, Lantz B, Angelin B. Non-steady-state kinetics of low density lipoproteins in man-studies after plasma exchange in healthy subjects and patients with familial hypercholesterolaemia. Eur J Clin Invest 1993;23:746-52.
10. Naoumova RP, Marais D, Firth JC, Neuwirth CKY, Taylor GW, Thompson GR. Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting upregulation of cholesterol synthesis after apheresis and bile acid sequestrants. Circulation 1996;94:I-583.
11. Armstrong VW, Schleef J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T, Seidel D. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein (a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest 1989;19:235-40.
12. Gordon BR, Saal SD. Current status of low density lipoproteinapheresis for the therapy of severe hyperlipidemia. Curr Opin Lipidol 1996;7:381-4.
13. Kassner U, Schaper J, Münzberg H, Steinhagen-Thiessen E. Treatment of hyperlipoproteinemia(a) with LDL-apheresis in order to stop progredient coronary heart disease (a case report). Atherosclerosis 1997; 134:142.
14. Parhofer KG, Ritter MM, Geiss C, Schwandt P. Lipoprotein (a) metabolism in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1997; 134:146.
15. Parhofer KG, Barrett PHR, Demant T, Richter WO, Schwandt P. Effects of weekly LDL apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia. J Lipid Res 1996;37:2383-93.
16. Parhofer KG, Barrett PHR, Demant T, Richter WO, Schwandt P. Effect of apheresis on kinetic parameters of apolipoprotein B metabolism in familial hypercholesterolemia. Circulation 1996;90:I-583.
17. Apstein CS, Zilversmit DB, Lees RS, George PK. Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis 1978;31:10515.
18. Kramer MS, Feinstein AR. Clinical biostatistics: the biostatistics of concordance. Clin Pharmacol Ther 1981;29:111-23.
19. Fleiss JL. Measuring agreement between two judges on the presence or absence of a trait. Biometrics 1975;31:651-9.
20. Gaw A, Packard CJ, Lindsay GM, Murray EF, Griffin BA, Caslake MJ, Colquhoun I, Wheatley DJ, Lorimer AR, Shepard J. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Arterioscler Thromb Vase Biol 1996;16:236-49.
21. Streicher J, Valent P, Schmidt H, Sengoelge G, Banyai S, Hoerl WH, Derfler K. Stimulation of LDL receptor expression by LDL-immuno-apheresis in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1997;134:362.
22. Grundy SM, Vega GL, Bilheimer DW. Effects of combined therapy with mevinolin and interruption of bile acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia. Ann Intern Med 1985;103:339-43.
23. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983;80:4124-8.
24. Barrett PHR, Parhofer KG. LDL-Apolipoprotein B Metabolism Following Apheresis: Simulation Studies of Mass Changes and Tracer Kinetics. Metabolism 1998;47:478-83.
25. Foster DM, Chait A, Albers J, Failor RA, Harris C, Brunzell JD. Evidence for kinetic heterogeneity among human low density lipoproteins. Metabolism 1986;35:685-96.
26. Pietzsch J, Wiedemann B, Julius U, Nitzsche S, Gehrisch S, Bergmann S, Leonhardt W, Jaross W, Hanefeld M. Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach. J Lipid Res 1996;37:2074-87.
27. Demant T, Packard CJ, Demmelmair H, Stewart P, Bedynek A, Bedford D, Seidel D, Shepherd J. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. Am J Physiol 1996;270:E1022-36.
28. Parhofer KG, Barren PHR, Dunn J, Schonfeld G. Effect of pravastatin on metabolic parameters of apolipoprotein-B in patients with mixed hyperlipoproteinemia. Clin Invest 1993;71:939-46.